相关实验视频

Updated: Jul 5, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

对结直肠癌药物治疗的最新情况:2023年及以后

Mengou Zhu¹, Al B Benson^2,3

¹Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Expert opinion on pharmacotherapy

|January 15, 2024

概括

向治疗和基因测试,包括下一代测序 (NGS),正在改善转移性结直肠癌 (mCRC) 的结果. 早期的NGS使用辅助在选择个性化药物治疗中,以获得更好的CRC治疗结果.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药物治疗药物治疗

背景情况:

结肠直肠癌 (CRC) 是全球癌症相关死亡的主要原因.
转移性CRC (mCRC) 与局部或区域CRC相比,具有较低的存活率,具有显著的治疗挑战.
药物治疗研究旨在改善CRC的治疗结果.

研究的目的:

审查关于CRC药物治疗的当前文献和临床试验.
专注于基因检测结果指导的向疗法.
讨论用于治疗CRC的新药和诊断方法.

主要方法:

关于CRC药物治疗当前研究和正在进行的临床试验的文献综述.
专注于向治疗,包括抗EGFR,VEGF通路和NTRK融合的药物.
基于不匹配修复 (MMR) 或微卫星不稳定 (MSI) 状态的免疫疗法的评估.
讨论下一代测序 (NGS) 用于治疗选择和监测.

主要成果:

针对特定途径 (EGFR,VEGF) 的新型药物在CRC治疗中表现有前途.
对于具有特定MMR/MSI个人资料的患者,可提供免疫疗法选择.
针对基因融合的向疗法,如NTRK,为治疗提供了新的途径.
下一代测序 (NGS) 对于指导治疗选择和监测反应非常有价值.

结论:

建议早期和常规使用NGS用于CRC的遗传特征.
NGS促进了个性化药理疗选择,改善了治疗结果.
向治疗是CRC管理中的一个有希望和不断发展的领域.

关键词:

结肠直肠癌是一种癌症.欧洲农业基金会 (EGFR) 是一个基金.在 dMMR/MSI 中使用.免疫疗法免疫疗法转移性结直肠癌转移性结直肠癌这是下一代测序.在 pMMR/MSS中,有针对性的治疗.

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...